Does Wellbutrin (bupropion) improve cognition?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Wellbutrin Does Not Improve Cognition as a Primary Indication

Wellbutrin (bupropion) is not recommended for treating cognitive impairment as a standalone indication. The FDA-approved drug label explicitly warns that bupropion may impair cognitive and motor skills, advising patients to refrain from complex tasks until they know how the medication affects them 1. While some research suggests potential cognitive benefits in specific contexts, the evidence is inconsistent and does not support using bupropion primarily for cognitive enhancement.

Evidence from FDA Drug Labeling

The official FDA labeling for Wellbutrin XL clearly states that "any CNS-active drug like Wellbutrin XL may impair their ability to perform tasks requiring judgment or motor and cognitive skills" 1. This is a critical safety warning that directly contradicts the premise of using bupropion to improve cognition. Patients are explicitly advised to avoid driving or operating complex machinery until they understand how the medication affects their performance.

Context-Specific Findings

Depression-Related Cognitive Impairment

When bupropion improves cognition, it appears to be secondary to treating the underlying depression, not a direct procognitive effect:

  • In major depressive disorder (MDD), both bupropion and escitalopram improved verbal memory, nonverbal memory, and working memory equally over 8 weeks 2. The improvement in immediate verbal memory directly influenced global function improvement, suggesting the cognitive benefits were tied to depression resolution rather than a unique drug effect.

  • A systematic review found that bupropion demonstrated procognitive effects relative to SSRIs and SNRIs in MDD populations 3, but this was in the context of treating depression, not cognitive impairment alone.

  • One older study in elderly depressives found that cognition improved equally in bupropion, imipramine, and placebo groups 4, suggesting no specific cognitive advantage.

Smoking Cessation Context

In tobacco abstinence, bupropion showed modest effects on withdrawal-related cognitive deficits:

  • Bupropion improved working memory response times and some sustained attention measures on the first day of tobacco abstinence 5. This appears to be relief of nicotine withdrawal symptoms rather than cognitive enhancement.

Alzheimer's Disease - Negative Results

Critically, bupropion failed to improve apathy or cognition in Alzheimer's disease 6. In a well-designed 12-week RCT of 108 patients with mild-to-moderate Alzheimer's dementia, bupropion showed no superiority over placebo for apathy (primary outcome) or cognition (mean change -0.27; 95% CI -3.26 to 2.73; P=0.86). This directly contradicts any notion that bupropion has meaningful procognitive effects in neurodegenerative conditions.

Anecdotal COVID-19 Brain Fog Reports

Two case reports suggested bupropion helped COVID-19-related brain fog 7, but case reports represent the lowest quality evidence and cannot establish efficacy. The proposed mechanisms (blocking hippocampal cell loss, increasing cingulate cortex activity, decreasing inflammatory cytokines) are speculative and unproven in this context.

Clinical Interpretation

The pattern across studies reveals that:

  1. Any cognitive improvements with bupropion occur primarily when treating depression, not as a direct cognitive enhancer
  2. The FDA explicitly warns about potential cognitive impairment from bupropion
  3. In pure cognitive disorders (Alzheimer's), bupropion showed no benefit
  4. Modest effects in smoking cessation appear related to withdrawal relief, not cognitive enhancement

Common Pitfalls to Avoid

  • Do not prescribe bupropion specifically for cognitive complaints without an underlying indication like depression or smoking cessation
  • Do not assume cognitive improvements in depression studies translate to cognitive enhancement in cognitively normal individuals
  • Monitor for cognitive impairment when initiating bupropion, especially in patients performing complex tasks
  • Avoid in patients with seizure disorders or brain metastases 8, as bupropion lowers seizure threshold (0.1% risk) 8

Appropriate Clinical Uses

Bupropion remains indicated for:

  • Major depressive disorder (where cognitive improvements may occur as depression resolves)
  • Smoking cessation (where it may attenuate withdrawal-related cognitive deficits)
  • Weight management (as naltrexone-bupropion combination) 9, 10, 11

In these contexts, any cognitive benefits are secondary to treating the primary condition, not a reason to prescribe the medication.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.